Title:
PREVENTIVE OR THERAPEUTIC AGENT FOR DIABETIC RETINOPATHY
Document Type and Number:
WIPO Patent Application WO/2020/241660
Kind Code:
A1
Abstract:
Provided is a novel preventive or therapeutic agent for diabetic retinopathy against which the development of effective therapeutic agents has been desired. This preventive or therapeutic agent for diabetic retinopathy contains a neutralizing antibody against secreted eIF5A as an active ingredient.
More Like This:
Inventors:
SEKO YOSHINORI (JP)
MURAYAMA KIMIE (JP)
FUJIMURA TSUTOMU (JP)
MORI TAKAKO (JP)
UEMURA AKIYOSHI (JP)
MURAYAMA KIMIE (JP)
FUJIMURA TSUTOMU (JP)
MORI TAKAKO (JP)
UEMURA AKIYOSHI (JP)
Application Number:
PCT/JP2020/020835
Publication Date:
December 03, 2020
Filing Date:
May 27, 2020
Export Citation:
Assignee:
JUNTENDO EDUCATIONAL FOUND (JP)
UNIV NAGOYA CITY PUBLIC UNIV CORP (JP)
UNIV NAGOYA CITY PUBLIC UNIV CORP (JP)
International Classes:
A61K39/395; A61P9/10; A61P27/02; C07K16/18
Domestic Patent References:
| WO2009144933A1 | 2009-12-03 |
Other References:
SEKO, Y. ET AL.: "Secreted tyrosine sulfated-eIF5A mediates oxidative stress- induced apoptosis", SCIENTIFIC REPORTS, vol. 5, no. 13737, 2015, XP055767226
SUZUKI, Y. ET AL.: "Elevation of the vitreous body concentrations of oxidative stress-responsive apoptosis-inducing protein (ORAIP) in proliferative diabetic retinopathy", GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol. 257, 6 May 2019 (2019-05-06), pages 1519 - 1525, XP036802962, DOI: 10.1007/s00417-019-04343-w
SUZUKI, Y. ET AL.: "Elevation of the vitreous body concentrations of oxidative stress-responsive apoptosis-inducing protein (ORAIP) in proliferative diabetic retinopathy", GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol. 257, 6 May 2019 (2019-05-06), pages 1519 - 1525, XP036802962, DOI: 10.1007/s00417-019-04343-w
Attorney, Agent or Firm:
THE PATENT CORPORATE BODY ARUGA PATENT OFFICE (JP)
Download PDF: